Accuray Incorporated (NASDAQ:ARAY) specializes in developing and selling radiation therapy systems for cancer treatment. On February 4, 2026, ARAY reported its earnings after the market closed, revealing an earnings per share (EPS) of -$0.11, which was below the estimated EPS of -$0.02. Additionally, ARAY's actual revenue was $102.24 million, falling short of the estimated $121.19 million.
During the Q2 2026 earnings call, as highlighted by Seeking Alpha, Accuray's management discussed the company's financial performance and strategic initiatives. CEO Steve La Neve emphasized the company's focus on four key pillars: commercial simplification, global functional alignment, elevation of service and product development, and optimization of cost structure and footprint. These initiatives aim to accelerate top-line growth and enhance overall performance.
Despite the earnings miss, ARAY's financial metrics provide some insights into its valuation and financial health. The company has a price-to-sales ratio of 0.19, indicating that investors are paying 19 cents for every dollar of sales. Its enterprise value to sales ratio is 0.45, suggesting a moderate valuation relative to its sales. These figures suggest that the market may see potential in ARAY's future growth.
ARAY's enterprise value to operating cash flow ratio is 9, which implies that the company is generating cash flow efficiently relative to its enterprise value. However, the company has a debt-to-equity ratio of approximately 2.90, indicating a higher level of debt compared to its equity. This could be a concern for investors, as it suggests a reliance on debt financing.
On the liquidity front, ARAY has a current ratio of 1.55, suggesting that the company has a good level of liquidity to cover its short-term liabilities. This indicates that despite the earnings miss, ARAY is in a position to meet its short-term obligations, which is a positive sign for its financial stability.
